Predicting Bleeding in AML-Associated DIC: Limitations of the ISTH Score and a Modified Approach

dc.contributor.authorOrhan, Bedrettin
dc.contributor.authorOzkalemkas, Fahir
dc.contributor.authorBayir, Tuba
dc.contributor.authorYalcin, Cumali
dc.contributor.authorGuner, Busra
dc.contributor.authorElgun, Ezel
dc.contributor.authorOzkocaman, Vildan
dc.date.accessioned2026-08-12T17:42:49Z
dc.date.issued2025
dc.departmentFırat Üniversitesi
dc.description.abstractBackground and Objectives: Bleeding is a major cause of mortality in cases of acute myeloid leukemia (AML)-associated disseminated intravascular coagulation (DIC). The predictive power of the standard International Society on Thrombosis and Hemostasis (ISTH) score for bleeding in patients diagnosed with AML is limited. This study aimed to evaluate the performance of the standard ISTH score and modified versions in predicting bleeding among acute promyelocytic leukemia (APL, M3) and non-APL AML subgroups. Methods: This single-center, retrospective study included 190 AML patients (61 APL, 129 non-APL). The predictive power of the original ISTH score and eight different modified scores-incorporating parameters such as lactate dehydrogenase (LDH) and genetic positivity-for DIC-related bleeding was assessed using receiver operating characteristic (ROC) analysis. Results: In the APL group, the original ISTH score was statistically significant in predicting DIC-related bleeding (AUC = 0.727), but the modifications did not improve performance. In the non-APL AML group, the original score did not predict bleeding (AUC = 0.632, p = 0.079). However, a modified ISTH score excluding D-dimer and including LDH (>= 800 mg/dL) and genetic positivity significantly improved prediction (AUC = 0.710, p = 0.005). This modification increased specificity from 48.2% to 60.7% and sensitivity from 76.5% to 82.4%. Conclusions: A subtype-specific approach is required to predict bleeding risk in AML-associated DIC. Modified ISTH scores remain suboptimal for APL; however, a modified score incorporating LDH and genetic status represents a promising tool to identify non-APL AML patients at risk of bleeding and warrants prospective validation.
dc.identifier.doi10.3390/diagnostics15233053
dc.identifier.issn2075-4418
dc.identifier.issue23
dc.identifier.orcid0000-0003-3970-2344
dc.identifier.orcid0009-0001-6744-9676
dc.identifier.orcid0000-0002-4991-9830
dc.identifier.orcid0000-0001-5419-3221
dc.identifier.orcid0000-0002-5129-2977
dc.identifier.orcid0000-0001-9710-134X
dc.identifier.pmid41374437
dc.identifier.scopus2-s2.0-105024595577
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.3390/diagnostics15233053
dc.identifier.urihttps://hdl.handle.net/11508/59880
dc.identifier.volume15
dc.identifier.wosWOS:001635466100001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofDiagnostics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectacute myeloid leukemia
dc.subjectbleeding
dc.subjectdisseminated intravascular coagulation
dc.subjectgenetics
dc.titlePredicting Bleeding in AML-Associated DIC: Limitations of the ISTH Score and a Modified Approach
dc.typeArticle

Dosyalar